The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
 
Heather A. Wakelee
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst); Xcovery (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck
 
Nasser K. Altorki
Stock and Other Ownership Interests - Angiocrine Bioscience; tomorrow; View Point Medical
Honoraria - AstraZeneca; Regeneron
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst)
 
Caicun Zhou
Honoraria - Boehringer Ingelheim; Hengrui Therapeutics; Innovent Biologics; Lilly; MSD; QiLu Pharmaceutical; Roche
Consulting or Advisory Role - Amoy Diagnostics; Hengrui Therapeutics; Innovent Biologics; QiLu Pharmaceutical
 
Tibor Csőszi
Consulting or Advisory Role - Novartis
Speakers' Bureau - Ipsen; Janssen-Cilag
Travel, Accommodations, Expenses - Pfizer; Sanofi
 
Ihor O. Vynnychenko
No Relationships to Disclose
 
Oleksandr Goloborodko
No Relationships to Disclose
 
Achim Rittmeyer
Consulting or Advisory Role - AbbVie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb; Lilly; MSD; Novartis; Roche/Genentech
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline K.K.; IO Biotech; IO Biotech; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Alex Martinez-Marti
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; MSD Oncology; Pfizer; Roche
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche
 
Hirotsugu Kenmotsu
Honoraria - Amgen; AstraZeneca; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Kyowa Hakko Kirin; Lilly; Merck; MSD K.K; Nihonkayaku; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Loxo (Inst); Novartis (Inst)
 
Yuh-Min Chen
No Relationships to Disclose
 
Antonio Chella
No Relationships to Disclose
 
Shunichi Sugawara
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; TOWA PHARMACEUTICAL
Research Funding - Abbvie (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst)
 
Chenqi Fu
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Marcus Ballinger
Employment - Genentech
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - co-inventor of an unpublished patent application (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Yu Deng
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Minu K Srivastava
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Travel, Accommodations, Expenses - Genentech
 
Elizabeth Bennett
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Barbara Jenifer Gitlitz
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023